Janux Therapeutics’ (JANX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report report published on Monday morning, Benzinga reports. They currently have a $63.00 target price on the stock. HC Wainwright also issued estimates for Janux Therapeutics’ Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.41) EPS, FY2024 earnings at ($1.21) EPS, Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($1.83) EPS.

Several other equities research analysts also recently issued reports on the stock. Wedbush restated an outperform rating and set a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. Cantor Fitzgerald reissued an overweight rating and set a $100.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Scotiabank reduced their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a sector perform rating on the stock in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $65.57.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $44.20 on Monday. Janux Therapeutics has a one year low of $5.65 and a one year high of $65.60. The stock’s fifty day simple moving average is $41.31 and its 200 day simple moving average is $40.34. The firm has a market cap of $2.29 billion, a price-to-earnings ratio of -36.23 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The business had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. The company’s quarterly revenue was up 709.1% on a year-over-year basis. On average, research analysts anticipate that Janux Therapeutics will post -1.34 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In other news, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $37,081,025.25. Following the completion of the sale, the insider now directly owns 3,271,216 shares of the company’s stock, valued at $179,099,076. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Janux Therapeutics news, Director Jay Lichter sold 1,500,000 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $82,125,000.00. Following the sale, the director now owns 633,673 shares in the company, valued at $34,693,596.75. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $37,081,025.25. Following the completion of the transaction, the insider now directly owns 3,271,216 shares of the company’s stock, valued at $179,099,076. The disclosure for this sale can be found here. Insiders sold a total of 3,000,000 shares of company stock valued at $164,250,000 in the last quarter. 35.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors have recently made changes to their positions in JANX. Amalgamated Bank increased its holdings in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares during the period. Summit Securities Group LLC bought a new position in shares of Janux Therapeutics in the second quarter worth approximately $29,000. Plato Investment Management Ltd purchased a new position in shares of Janux Therapeutics in the second quarter worth $42,000. Nisa Investment Advisors LLC grew its stake in shares of Janux Therapeutics by 10,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock worth $29,000 after acquiring an additional 2,685 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Janux Therapeutics during the 2nd quarter valued at $151,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.